MucoLife Therapeutics CEO, Thaher Pelaseyed, to present breakthrough COPD treatment at BioNTX iC³ Summit in Arlington, Texas
Dallas (TX), USA – [20241002] – Thaher Pelaseyed, PhD, CEO and co-founder of MucoLife Therapeutics, will attend the BioNTX iC³ Life Science and Healthcare Innovation Summit in Arlington, TX, where he will present the company's revolutionary approach to treating Chronic Obstructive Pulmonary Disease (COPD). Dr. Pelaseyed will pitch MucoLife’s first-in-class inhaled therapeutic, MLT-001, designed to dissolve mucus plugs and transform COPD treatment.
MucoLife Therapeutics is a Swedish start-up pioneering a novel solution to a critical unmet need in COPD care. MLT-001, their lead product, targets mucus obstruction in the lungs—a major cause of respiratory complications in COPD patients. This breakthrough treatment has demonstrated a 90% effectiveness in preclinical trials at clearing airways and improving lung function. The company recently partnered with Health Wildcatters, a top-ranked seed accelerator based in Dallas (TX), to advance their product to clinical trials.
“MLT-001 is a game changer in COPD care. By directly dissolving mucus plugs, we can improve patients' quality of life and potentially slow disease progression,” said Dr. Pelaseyed. “I’m excited to share our innovation at the iC³ Summit and discuss potential collaborations to bring this much-needed therapy to market.”
With COPD affecting over 50 million people in Europe and the U.S., MucoLife Therapeutics is strategically positioned to disrupt the $23 billion COPD drug market. Their business strategy focuses on the development and commercialization of this first-in-class therapy, with plans to expand into other mucus-related respiratory diseases such as asthma and cystic fibrosis.
Dr. Pelaseyed will be presenting on Friday October 4, 09.10-09.50 during Session 4/Ballroom F at the iC³ Summit.
For more information, visit www.mucolife.com.
About MucoLife Therapeutics
MucoLife Therapeutics pioneers a novel approach for treating mucus obstruction in COPD. MLT-001 is the company’s first-in-class product that dissolves mucus plugs in the airways, thereby improving lung function and preventing inflammation and infections.
About BioNTX iC³ Summit
The iC³ Summit is a dynamic platform for the North Texas bioscience and healthcare community to engage in thoughtful discussions, share cutting-edge research, and explore emerging technologies with potential to revolutionize the future of biotechnology, health care and human health.
Press contact MucoLife Therapeutics:
Thaher Pelaseyed, PhD
Co-founder/CEO
MucoLife Therapeutics
tpelaseyed@mucolife.com
+46 733 79 43 47